Novavax, Inc. (NVAX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 22 | 198 | 1,599 | 556 | 682 | 1,123 | 414 | 376 |
| Operating profit | $m | 563 | -227 | ||||||
| Net profit | $m | -418 | -1,744 | -658 | -545 | -187 | 440 | -248 | -73 |
| EPS reported | $ | 2.54 | -1.52 | ||||||
| Operating cashflow per share | $ | -1.51 | -0.24 | ||||||
| Capex per share | $ | 0.03 | 0.02 | ||||||
| FCF per share | $ | -1.54 | -0.26 | ||||||
| Free cash flow | $m | -250 | -44 | ||||||
| Net debt | $m | -491 | -430 | ||||||
| Book value equity | $m | -128 | -191 | ||||||
| Book value per share | $ | -0.74 | -1.16 | ||||||
| Number of shares | m | 173.1 | 164.57 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 2.65 | - | ||||||
| P/B LTM | x | -8.52 | -5.71 | ||||||
| P/S LTM | x | 0.97 | 2.63 | ||||||
| P/FCF LTM | x | -4.35 | -24.97 | ||||||
| EV/EBITDA LTM | x | 2.23 | -5.42 | ||||||
| EV/Sales LTM | x | 0.98 | 3.45 | ||||||
| Earnings Yield LTM | % | +37.74% | -18.70% | ||||||
| FCF Yield | % | -22.98% | -4.00% | ||||||
| Quality | |||||||||
| ROE | % | -344.65% | +159.85% | ||||||
| ROIC | % | +78.00% | -36.14% | ||||||
| Operating margin | % | +50.14% | -54.94% | ||||||
| Gross margin | % | +93.67% | +77.85% | ||||||
| FCF/Sales | % | -22.27% | -10.53% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +64.69% | -39.34% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.01 | -0.15 | ||||||
| Net Debt/EBITDA | x | 0.02 | -0.51 | ||||||
| EBIT/Net interest | x | 24.98 | -18.80 | ||||||
| Net debt/market cap | % | +22.43% | +21.89% | ||||||
| Net debt/Equity | x | 3.84 | 2.25 | ||||||
| Gross debt/equity | x | -1.95 | -1.55 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free